Scarica l'app Stockscreener
2.60
1.17%
0.03
Dopo l'orario di chiusura:
2.59
-0.01
-0.38%
Precedente Chiudi:
$2.57
Aprire:
$2.57
Volume 24 ore:
623.25K
Relative Volume:
0.53
Capitalizzazione di mercato:
$148.13M
Reddito:
-
Utile/perdita netta:
$-82.44M
Rapporto P/E:
-1.383
EPS:
-1.88
Flusso di cassa netto:
$-66.75M
1 W Prestazione:
+4.42%
1M Prestazione:
-2.62%
6M Prestazione:
+0.78%
1 anno Prestazione:
+22.07%
Intervallo 1D:
$2.525
$2.615
Intervallo di 1 settimana:
$2.41
$2.615
Portata 52W:
$1.195
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Nome
Black Diamond Therapeutics Inc
Settore
Industria
Telefono
617-417-5868
Indirizzo
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Confronta BDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.60 | 146.43M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-11-18 | Ripresa | Piper Sandler | Overweight |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2024-07-31 | Iniziato | Raymond James | Outperform |
| 2023-07-14 | Iniziato | Piper Sandler | Overweight |
| 2023-06-30 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-03-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-03-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-01-07 | Iniziato | Wedbush | Outperform |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | Canaccord Genuity | Buy |
| 2020-02-24 | Iniziato | Cowen | Outperform |
| 2020-02-24 | Iniziato | JP Morgan | Overweight |
| 2020-02-24 | Iniziato | Jefferies | Buy |
Mostra tutto
Black Diamond Therapeutics Inc Borsa (BDTX) Ultime notizie
What drives Black Diamond Therapeutics Inc stock priceReal Estate Investment Trusts & Download Your Free Wealth Map PDF - earlytimes.in
Evoke Pharma Leads Stock Performance with 148.87% Return in Pharmaceuticals Sector - Markets Mojo
Black Diamond Therapeutics’ Silevertinib shows 60% response rate in preliminary phase 2 lung cancer data - MSN
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Insider Monkey
What analysts say about Black Diamond Therapeutics Inc stockCandlestick Trading Patterns & High Return Trading Ideas - earlytimes.in
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to NASDAQ Biotechnology Index - marketscreener.com
Why Black Diamond Therapeutics Inc. stock could benefit from AI revolutionTrade Analysis Report & AI Based Buy/Sell Signal Reports - Улправда
BDTX (Black Diamond Therapeutics) EV-to-OCF : 1.30 (As of Dec. 21, 2025) - GuruFocus
Can Black Diamond Therapeutics Inc. stock deliver strong Q4 earnings2025 Institutional Moves & Daily Market Momentum Tracking - DonanımHaber
What margin trends mean for Black Diamond Therapeutics Inc. stockMarket Performance Recap & Verified Short-Term Trading Plans - DonanımHaber
Can Black Diamond Therapeutics Inc. stock withstand economic slowdown2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
What momentum indicators show for Black Diamond Therapeutics Inc. stockWeekly Stock Summary & Accurate Trade Setup Notifications - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Cullinan Management (CGEM) - The Globe and Mail
Black Diamond Therapeutics (BDTX) director receives 4,665 share award - Stock Titan
Black Diamond Therapeutics (BDTX) – Analysts’ Weekly Ratings Updates - Defense World
A strong week for data readouts: Clinical Report - BioCentury
Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) - sharewise.com
Can Black Diamond Therapeutics Inc. stock continue upward trendGap Down & Long-Term Investment Growth Plans - Newser
Will Black Diamond Therapeutics Inc. stock attract more institutional investorsInsider Selling & Technical Pattern Based Buy Signals - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Lowered by Guggenheim - MarketBeat
Stifel reiterates Buy rating on Black Diamond Therapeutics stock at $8 - Investing.com Australia
Analyst Downgrades BDTX to Neutral from Buy | BDTX Stock News - GuruFocus
This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
How Black Diamond Therapeutics Inc. stock reacts to oil pricesBond Market & Consistent Profit Trade Alerts - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded by Guggenheim to Neutral - Defense World
Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Sahm
Are Smart Investors Making the Right Decision? Black Diamond Therapeutics Inc (BDTX) - Setenews
US Stocks Mixed; Dollar Tree Posts Upbeat Earnings - Benzinga
Black Diamond Therapeutics announces preliminary Phase 2 data for Silevertinib in 1L NSCLC - marketscreener.com
Black Diamond Therapeutics (BDTX) Reveals Promising Phase 2 Tria - GuruFocus
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Black Diamond to present Phase 2 silevertinib trial results By Investing.com - Investing.com Canada
Black Diamond to present Phase 2 silevertinib trial results - Investing.com India
Black Diamond Therapeutics to Host Webcast on Phase 2 Clinical Trial Results of Silevertinib on December 3, 2025 - Quiver Quantitative
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times
Black Diamond Therapeutics to Host Webcast Presentation - GlobeNewswire
Black Diamond Therapeutics, Inc. (BDTX) -9.9% in Intraday Trading: Decline Amid Routine Activity - Stocks Telegraph
Is Black Diamond Therapeutics Inc a good long term investmentCandlestick Trading Patterns & Learn to Trade with Real-Time Feedback - earlytimes.in
Adversity is less terrifying than hope: Black Diamond Therapeutics Inc (BDTX) - Setenews
Aug Retail: Why Black Diamond Therapeutics Inc. stock could benefit from AI revolutionTrade Volume Report & Expert Curated Trade Ideas - moha.gov.vn
Black Diamond Therapeutics Inc. (BDTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about Black Diamond Therapeutics Inc. stockQuarterly Profit Review & Fast Exit and Entry Strategy Plans - newser.com
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout (NASDAQ:BDTX) - Seeking Alpha
Will Black Diamond Therapeutics Inc. stock pay special dividends2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Black Diamond Therapeutics Inc Azioni (BDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):